Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same

Patent metadata

Field	Value
Publication number	US-10627412-B2
Application number	US-201113635519-A
Country	US
Kind code	B2
Filing date	Mar 17, 2011
Priority date	Mar 17, 2010
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto.

First claim

The invention claimed is:

1. A method of detecting a peptide and/or autoantibodies to said peptide, wherein the peptide is selected from the group of peptides consisting of respective amino acid sequences shown by SEQ ID NOs: 1-3, 5 and 7-9 or orthologs and paralogs thereof as shown by SEQ ID NOs: 15-22 and 24-30 in a test animal, comprising:
(1) obtaining a biological sample selected from the group consisting of blood, plasma, serum, interdental liquid, urine and saliva from the test animal;
(2) measuring amounts of one or more peptides selected from the group of peptides consisting of respective amino acid sequences shown by SEQ ID NOs: 1-3, 5 and 7-9 or orthologs and paralogs thereof as shown by SEQ ID NOs: 15-22 and 24-30, and/or one or more autoantibodies selected from the group consisting of autoantibodies to respective peptides of said group of peptides, in the biological sample, wherein the amount(s) of the peptides and/or autoantibodies are measured by applying the biological sample to mass spectrometry, or by a method selected from enzyme-linked immunosorbent assay, radioimmunoassay, nephelometry and surface plasmon resonance.

2. A method for the diagnosis and treatment of a periodontal disease of a test animal, comprising:
(1) obtaining a biological sample selected from the group consisting of blood, plasma, serum, interdental liquid, urine and saliva from the test animal;
(2) measuring amounts of one or more peptides selected from the group of peptides consisting of respective amino acid sequences shown by SEQ ID NOs: 1-10 or orthologs and paralogs thereof as shown by SEQ ID NOs: 15-30, and/or one or more autoantibodies selected from the group consisting of autoantibodies to respective peptides of said group of peptides, in the biological sample, wherein the amount(s) of the peptides and/or autoantibodies are measured by applying the biological sample to mass spectrometry, or by a method selected from enzyme-linked immunosorbent assay, radioimmunoassay, nephelometry and surface plasmon resonance;
(3) diagnosing that the test animal has a high possibility of being affected with a periodontal disease when the amount(s) of the peptides and/or autoantibodies in the biological sample significantly increase as compared to those in a control sample obtained from a normal animal; and
(4) administering an effective amount of any of the peptides to an oral cavity of the animal to trap and remove an autoantibody to the peptide.

3. A method for evaluating the improvement of the condition of a periodontal disease, comprising:
(1) collecting biological samples selected from the group consisting of blood, plasma, serum, interdental liquid, urine and saliva from a patient in a chronological order;
(2) measuring time course changes of an amount of one or more peptides selected from the group of peptides consisting of respective amino acid sequences shown by SEQ ID NOs: 1-10 or orthologs and paralogs thereof as shown by SEQ ID NOs: 15-30, and/or one or more autoantibodies selected from the group consisting of autoantibodies to respective peptides of said group of peptides in the samples; and
(3) determining that the condition of the periodontal disease in the patient is improved when the amount(s) of the peptides and/or autoantibodies decrease over time,
wherein the patient is treated by administering an effective amount of any of the peptides to an oral cavity of the patient to trap and remove an autoantibody to the peptide.

4. The method according to claim 3 , further comprising treating the patient between a sampling and the next sampling, and evaluating the treatment effect in the patient by comparing changes of amounts of the peptides and/or autoantibodies in biological samples obtained from said patient before and after the treatment.

Assignees

• Maruyama Ikuro
• Hashiguchi Teruto
• Tancharoen Salunya
• Kawahara Ko Ichi
• Tanaka Kenji
• Lee Lyang Ja
• Univ Kagoshima

Inventors

• Maruyama Ikuro
• Hashiguchi Teruto
• Tancharoen Salunya
• Kawahara Ko-Ichi
• Tanaka Kenji
• Lee Lyang-Ja

Classifications

• G01N2333/4742

  Keratin; Cytokeratin · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title

• A61P1/02

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title

• G01N2800/18

  Dental and oral disorders · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title